netFormulary Joint Medicines Formulary NHS
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand.  
Chapter Links...
 Details...
08.02.04  Expand sub section  Other immunomodulating drugs
Dimethyl fumarate (Tecfidera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Dimethyl fumarate Capsules

    Available in line with NICE TA320 at the following specialist centres:
    Leeds Teaching Hospital Trust, Sheffield Teaching Hospital, Hull and East Yorkshire, York and Mid Yorks Trusts.
 
Link  MHRA Drug Safety Update: Dimethyl fumarate: fatal PML in an MS patient with severe, prolonged lymphopenia (March 2015)
Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (August 2014)
Link  NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis (September 2017)
 
Cytotoxic Drug Lenalidomide ( Revlimid®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
NHS England
BlueTeq
  • Lenalidomide Capsules

Use restricted to Consultant Haematologists only.
 
Lenalidomide is also available for other indications via the Cancer Drugs Fund.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 

 
Link  Cancer Drugs Fund - Lenalidomide
Link  Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
Link  Drug Safety Update: Lenalidomide (Revlimid®): New important advice regarding viral reactivation (November 2016)
Link  MHRA Drug Safety Update: Risk of thrombosis and thromboembolism (Feb 2011)
Link  NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (June 2009)
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014)
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
Link  NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (June 2019)
Link  NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (June 2019)
Link  NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma (April 2020)
 
Panobinostat (Farydak®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Panobinostat Capsules


Consultant haematologist only.

 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least two previous treatments (January 2016)
 
Cytotoxic Drug Pomalidomide (Imnovid®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Pomalidomide Capsules
     

Haematology use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
Link  MHRA Drug Safety Update: Pomalidomide (Imnovid„): risk of hepatitis B reactivation (April 2016)
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (January 2017)
 
Cytotoxic Drug Thalidomide
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Thalidomide Capsules

Consultant Haematologist use only

 
Link  Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
Link  Drug Safety Update: Thalidomide - reduced starting dose in patients older than age 75 years (December 2015)
Link  MHRA Drug Safety Update: Thalidomide: Risk of second primary malignancies (May 2013)
Link  MHRA Drug Safety Update: Thalidomide: risk of arterial and venous thromboembolism (July 2011)
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (July 2011)
 
08.02.04  Expand sub section  Interferon Alfa
Interferon Alfa
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Interferon Alfa-2A Injection

    Reserved for Consultant Haematologist use  
  •  
    Peginterferon Alfa
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Peginterferon Alfa-2B Prefilled Pen

    Consultant Gastroenterologist use only for the treatment of hepatitis C in combination with ribavirin capsules in line with NICE TA106, TA200 and TA75.

     
  • Link  NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (August 2006)
    Link  NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (September 2010)
    Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (November 2013)
     
    08.02.04  Expand sub section  Interferon beta
    08.02.04  Expand sub section  Aldesleukin
    08.02.04  Expand sub section  Glatiramer acetate to top
     note 

    Available via specialist centres only.

    08.02.04  Expand sub section  Natalizumab
     ....
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    Green - Drugs suitable for generalised use in accordance with position summary. Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.   

    Amber

    Amber - these drugs require specialist initiation or recommendation  

    Amber SCG

    Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.  

    Red

    Red - Drugs for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Red ULM

    Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Grey

    Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached.   

    Black

    Black - Drugs not routinely commissioned so should not usually be prescribed  

    netFormulary